Last reviewed · How we verify
Hereditary C1 esterase inhibitor deficiency - deficient factor — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Ruconest | CONESTAT ALFA | Pharming Group N.V. | 2010-01-01 | |||
| Ruconest | Ruconest | Bernstein Clinical Research Center |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bernstein Clinical Research Center · 1 drug in Hereditary C1 esterase inhibitor deficiency - deficient factor
- Pharming Group N.V. · 1 drug in Hereditary C1 esterase inhibitor deficiency - deficient factor
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Hereditary C1 esterase inhibitor deficiency - deficient factor:
- Hereditary C1 esterase inhibitor deficiency - deficient factor treatment updates — RSS
- Hereditary C1 esterase inhibitor deficiency - deficient factor treatment updates — Atom
- Hereditary C1 esterase inhibitor deficiency - deficient factor treatment updates — JSON
Cite this brief
Drug Landscape (2026). Hereditary C1 esterase inhibitor deficiency - deficient factor — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hereditary-c1-esterase-inhibitor-deficiency-deficient-factor. Accessed 2026-06-10.
Related
- Hereditary C1 esterase inhibitor deficiency - deficient factor full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing